Molecular Templates to Present at the Oppenheimer New York Oncology Insight Summit and the UBS Global Healthcare Conference
14 mai 2019 16h30 HE
|
Molecular Templates, Inc.
AUSTIN, Texas, May 14, 2019 (GLOBE NEWSWIRE) -- Molecular Templates, Inc., (Nasdaq: MTEM) a clinical stage biopharmaceutical company focused on the discovery and development of Engineered Toxin...
Molecular Templates, Inc. Reports First Quarter 2019 Financial Results
13 mai 2019 16h01 HE
|
Molecular Templates, Inc.
AUSTIN, Texas, May 13, 2019 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular” or “Molecular Templates”), a clinical-stage oncology company focused on the discovery and...
Molecular Templates Announces FDA Acceptance of IND Application for MT-5111, An Engineered Toxin Body Targeting HER2
22 avr. 2019 08h00 HE
|
Molecular Templates, Inc.
AUSTIN, Texas, April 22, 2019 (GLOBE NEWSWIRE) -- Molecular Templates, Inc., (Nasdaq: MTEM) a clinical stage biopharmaceutical company focused on the discovery and development of Engineered Toxin...
Molecular Templates’ Presentations at the American Association of Cancer Research (AACR) Annual Meeting 2019 Highlight Evolution of ETB Platform
02 avr. 2019 07h00 HE
|
Molecular Templates, Inc.
AUSTIN, Texas, April 02, 2019 (GLOBE NEWSWIRE) -- Molecular Templates, Inc., (Nasdaq: MTEM) a clinical stage biopharmaceutical company focused on the discovery and development of Engineered Toxin...
Molecular Templates, Inc. Reports Fourth Quarter 2018 Financial Results
28 mars 2019 16h30 HE
|
Molecular Templates, Inc.
AUSTIN, Texas, March 28, 2019 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular” or “Molecular Templates”), a clinical-stage oncology company focused on the discovery and...
Molecular Templates Announces Initiation of Phase II Monotherapy Study of MT-3724 in Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients
28 mars 2019 08h00 HE
|
Molecular Templates, Inc.
AUSTIN, Texas, March 28, 2019 (GLOBE NEWSWIRE) -- Molecular Templates, Inc., (Nasdaq: MTEM) a clinical stage biopharmaceutical company focused on the discovery and development of Engineered Toxin...
Molecular Templates to Present a Corporate Overview at the Cowen & Company 39th Annual and the Oppenheimer & Co. 29th Annual Health Care Conferences
05 mars 2019 16h30 HE
|
Molecular Templates, Inc.
AUSTIN, Texas, March 05, 2019 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM), a clinical stage biopharmaceutical company focused on the discovery and development of Engineered Toxin...
New Data on Molecular Templates’ Engineered Toxin Bodies to be Presented at the American Association of Cancer Research (AACR) Annual Meeting 2019
27 févr. 2019 17h00 HE
|
Molecular Templates, Inc.
AUSTIN, Texas, Feb. 27, 2019 (GLOBE NEWSWIRE) -- Molecular Templates, Inc., (Nasdaq: MTEM) a clinical stage biopharmaceutical company focused on the discovery and development of Engineered Toxin...
Molecular Templates Appoints Roger J. Waltzman, M.D., as Chief Medical Officer
19 févr. 2019 16h30 HE
|
Molecular Templates, Inc.
AUSTIN, Texas, Feb. 19, 2019 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM), a clinical-stage oncology company focused on the discovery and development of the company’s proprietary...
Molecular Templates to Present at the Evercore ISI and BMO Healthcare Conferences
26 nov. 2018 16h30 HE
|
Molecular Templates, Inc.
AUSTIN, Texas, Nov. 26, 2018 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM), a clinical-stage oncology company focused on the discovery and development of the company’s proprietary...